<DOC>
	<DOCNO>NCT01753466</DOCNO>
	<brief_summary>The investigator conduct six-week randomize control pilot trial ass feasibility safety increase water intake patient chronic kidney disease.The investigator study 30 patient ( age 30 80 estimate glomerular filtration rate 30 60 ml/min/1.73m2 microalbuminuria [ albumin creatinine ratio &gt; 2.8 mg/mmol ( female ) &gt; 2.0 mg/mmol male ) ] .The investigator randomize patient ( 2:1 ratio ) fluid-intervention group control group . Participants randomize hydration-intervention group ask consume 1.0 1.5 L water per day ( depend sex weight ) addition usual consume beverage , 6 week . Participants control group advise consume usual amount fluid . The investigator hypothesize patient able increase maintain high fluid intake stable blood chemistry , particularly serum sodium .</brief_summary>
	<brief_title>The Water Intake Trial : Pilot Phase</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>Age 3080 year Able provide inform consent willing complete followup visit . Estimated glomerular filtration rate 30 60 ml/min/1.73m2 Microalbuminuria [ albumin creatinine ratio &gt; 2.8 mg/mmol ( female ) &gt; 2.0 mg/mmol male ) ] Selfreported fluid intake &gt; 10 cups/day 24hr urine volume &gt; 3L . Enrolled another randomize control trial could influence intervention , outcomes data collection trial ( previously enrol trial ) Received one dialysis treatment past month Kidney transplant recipient ( wait list ) Pregnant breastfeed History kidney stone past 5 year Less two year life expectancy Serum sodium &lt; 130 mEq/L without suitable explanation Serum calcium &gt; 2.6 mmol/L without suitable explanation Currently take hydrochlorothiazide &gt; 25 mg/d , indapamide &gt; 1.25 mg/d , furosemide &gt; 40 mg , metolazone &gt; 2.5 mg/d Currently take lithium Patient fluid restriction ( &lt; 1.5 L day ) kidney disease , heart failure , liver disease , AND meet follow criterion : ) end stage disease ( heart leave ventricular ejection fraction &lt; 40 % , NYHA class 3 4 , end stage cirrhosis ) ii ) hospitalization secondary heart failure , ascites and/or anasarca</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>